Zimmer Biomet Holdings Inc (ZBH.N)
ZBH.N on New York Stock Exchange
110.32USD
20 Apr 2018
110.32USD
20 Apr 2018
Change (% chg)
$-0.42 (-0.38%)
$-0.42 (-0.38%)
Prev Close
$110.74
$110.74
Open
$111.06
$111.06
Day's High
$112.17
$112.17
Day's Low
$109.86
$109.86
Volume
491,514
491,514
Avg. Vol
311,549
311,549
52-wk High
$133.45
$133.45
52-wk Low
$104.28
$104.28
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 1.94 | December | 23 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 11 | 12 | 12 | 11 |
| (2) OUTPERFORM | 9 | 10 | 9 | 9 |
| (3) HOLD | 9 | 7 | 7 | 8 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.93 | 1.83 | 1.82 | 1.89 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 23 | 1,993.99 | 2,042.00 | 1,960.00 | 2,063.06 |
| Quarter Ending Sep-18 | 23 | 1,860.65 | 1,887.90 | 1,840.00 | 1,940.58 |
| Year Ending Dec-18 | 27 | 7,965.74 | 8,071.00 | 7,870.00 | 8,143.72 |
| Year Ending Dec-19 | 27 | 8,159.60 | 8,225.75 | 8,000.00 | 8,405.33 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 26 | 1.94 | 2.08 | 1.85 | 2.36 |
| Quarter Ending Sep-18 | 26 | 1.78 | 1.83 | 1.71 | 2.15 |
| Year Ending Dec-18 | 30 | 7.80 | 8.05 | 7.68 | 9.37 |
| Year Ending Dec-19 | 29 | 8.37 | 8.80 | 8.00 | 10.19 |
| LT Growth Rate (%) | 8 | 5.81 | 8.00 | 2.91 | 9.73 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-17 | 2,028.68 | 2,074.30 | 45.62 | 2.25 |
| Quarter Ending Sep-17 | 1,830.00 | 1,818.10 | 11.90 | 0.65 |
| Quarter Ending Jun-17 | 1,952.17 | 1,954.40 | 2.23 | 0.11 |
| Quarter Ending Mar-17 | 1,960.73 | 1,977.30 | 16.57 | 0.85 |
| Quarter Ending Dec-16 | 1,982.68 | 2,013.10 | 30.42 | 1.53 |
| Earnings (per share) | ||||
| Quarter Ending Dec-17 | 2.10 | 2.10 | 0.00 | 0.10 |
| Quarter Ending Sep-17 | 1.74 | 1.72 | 0.02 | 1.17 |
| Quarter Ending Jun-17 | 2.10 | 2.08 | 0.02 | 0.77 |
| Quarter Ending Mar-17 | 2.11 | 2.13 | 0.02 | 0.97 |
| Quarter Ending Dec-16 | 2.11 | 2.14 | 0.03 | 1.36 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 1,993.99 | 1,994.54 | 1,994.31 | 1,994.51 | 2,063.06 |
| Quarter Ending Sep-18 | 1,860.65 | 1,861.29 | 1,860.25 | 1,859.71 | 1,940.58 |
| Year Ending Dec-18 | 7,965.74 | 7,967.12 | 7,968.20 | 7,959.39 | 8,143.72 |
| Year Ending Dec-19 | 8,159.60 | 8,160.80 | 8,160.35 | 8,158.82 | 8,405.33 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 1.94 | 1.94 | 1.94 | 1.93 | 2.36 |
| Quarter Ending Sep-18 | 1.78 | 1.78 | 1.78 | 1.78 | 2.15 |
| Year Ending Dec-18 | 7.80 | 7.80 | 7.80 | 7.81 | 9.37 |
| Year Ending Dec-19 | 8.37 | 8.38 | 8.39 | 8.41 | 10.19 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 1 | 3 | 2 | 4 |
| Quarter Ending Sep-18 | 1 | 3 | 2 | 4 |
| Year Ending Dec-18 | 2 | 2 | 3 | 5 |
| Year Ending Dec-19 | 2 | 2 | 3 | 6 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 1 | 0 | 3 |
| Quarter Ending Sep-18 | 1 | 0 | 1 | 1 |
| Year Ending Dec-18 | 1 | 0 | 1 | 3 |
| Year Ending Dec-19 | 0 | 1 | 0 | 4 |
Earnings vs. 
Estimates- BRIEF-Zimmer Biomet Announces FDA Clearance And First Surgical Case Of The Persona Trabecular Metal Tibia
- BRIEF-Zimmer Biomet Says CEO Hanson's FY'17 Total Compensation Was $16.3 Mln
- BRIEF-Zimmer Biomet Holdings Files For Offering Of Floating Rate Notes Due 2021
- BRIEF-Zimmer Biomet Holdings Reports Q4 EPS Of $6.16
- BRIEF-Zimmer Biomet Holdings Announces FDA Clearance Of Sidus Stem-Free Shoulder System